Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled study of ATH008 cream for palmar-plantar erythrodysesthesia syndrome secondary to capecitabine
2010-022439-12Phase 2Completed
- Sponsor
- AdvanCell
- Start
- Nov 2010
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of ATH008 in Erythrodysesthesia syndrome (PPE) (3 arms), sponsored by AdvanCell. Primary endpoint: Safety variables. Started Nov 2010; status: completed.
02
Drugs
ATH008
03
Conditions
Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on 2010-022439-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022439-12.